{"id":"W2722759707","doi":"10.1200/jco.2017.35.15_suppl.e13525","title":"BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Temozolomide; Oncology; Cancer; Bevacizumab; Pharmacology; Gastroenterology; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226051,0.001574938,0.001507855,0.000578982,0.000378006,0.0007220794,0.0008257066,0.001062119,0.003119374],"category_scores_gemma":[0.0004445946,0.0005337669,0.0009066025,0.0004129847,0.0007696574,0.0006366212,0.0003739671,0.002754632,0.001241294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008870998,"about_ca_system_score_gemma":0.001496068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001809234,"about_ca_topic_score_gemma":0.004946559,"domain_scores_codex":[0.9997078,0.0001196054,0.00001582766,0.00004783739,0.00003393664,0.00007491864],"domain_scores_gemma":[0.9996496,0.00003495439,0.00006155579,0.0000248283,0.00002721363,0.0002018025],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3922864,0.1478064,0.01172878,0.001930184,0.001840277,0.0008526541,0.000740702,0.003753566,0.2138299,0.0005583151,0.01010215,0.2145706],"study_design_scores_gemma":[0.3233218,0.6354197,0.02043255,0.00006484331,0.0004836404,0.0008325263,0.0001053866,0.001660406,0.01209914,0.0001710519,0.005363897,0.00004503445],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990459,0.002389495,0.0006942549,0.0005608097,0.000107018,0.002331288,0.001368852,0.0001785032,0.00191083],"genre_scores_gemma":[0.9859385,0.002825127,0.001919489,0.0008745794,0.0001343661,0.00192301,0.003488064,0.00004722461,0.002849715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003119374,"threshold_uncertainty_score":0.01043534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2930263292070344,"score_gpt":0.5846921575951359,"score_spread":0.2916658283881016,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}